CPIX — Cumberland Pharmaceuticals Balance Sheet
0.000.00%
- $69.42m
- $66.43m
- $37.87m
- 58
- 39
- 91
- 67
Annual balance sheet for Cumberland Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 24.8 | 27 | 19.8 | 18.3 | 18 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 12.4 | 6.88 | 13.2 | 9.76 | 11.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 50 | 45.7 | 45.9 | 35.7 | 36.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.6 | 1.47 | 5.5 | 7.04 | 6.45 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 96.5 | 84.5 | 92.9 | 81.8 | 75.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 25.7 | 19.3 | 28.6 | 28 | 31.6 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 49.5 | 41.6 | 56.7 | 52.2 | 52.7 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 47 | 42.8 | 36.3 | 29.6 | 22.9 |
Total Liabilities & Shareholders' Equity | 96.5 | 84.5 | 92.9 | 81.8 | 75.6 |
Total Common Shares Outstanding |